Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Zevra Therapeutics Inc (NASDAQ: ZVRA) was $8.33 for the day, down -6.93% from the previous closing price of $8.95. In other words, the price has decreased by -$6.93 from its previous closing price. On the day, 1.22 million shares were traded. ZVRA stock price reached its highest trading level at $8.95 during the session, while it also had its lowest trading level at $8.31.
Ratios:
Our analysis of ZVRA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.81 and its Current Ratio is at 7.85. In the meantime, Its Debt-to-Equity ratio is 0.53 whereas as Long-Term Debt/Eq ratio is at 0.53.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on July 02, 2025, initiated with a Buy rating and assigned the stock a target price of $26.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 19 ’25 when Bode John B bought 5,000 shares for $9.16 per share. The transaction valued at 45,825 led to the insider holds 45,000 shares of the business.
Thompson Rahsaan sold 24,000 shares of ZVRA for $221,004 on Jun 26 ’25. The Chief Legal & Compliance now owns 42,666 shares after completing the transaction at $9.21 per share. On Jun 26 ’25, another insider, RAHSAAN THOMPSON, who serves as the Officer of the company, bought 24,000 shares for $9.33 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZVRA now has a Market Capitalization of 467605376 and an Enterprise Value of 327270304. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.54 while its Price-to-Book (P/B) ratio in mrq is 3.91. Its current Enterprise Value per Revenue stands at 5.277 whereas that against EBITDA is -6.078.
Stock Price History:
The Beta on a monthly basis for ZVRA is 1.50, which has changed by 0.15373957 over the last 52 weeks, in comparison to a change of 0.18189907 over the same period for the S&P500. Over the past 52 weeks, ZVRA has reached a high of $13.16, while it has fallen to a 52-week low of $6.19. The 50-Day Moving Average of the stock is -20.97%, while the 200-Day Moving Average is calculated to be -5.07%.
Shares Statistics:
ZVRA traded an average of 1.24M shares per day over the past three months and 998730 shares per day over the past ten days. A total of 56.14M shares are outstanding, with a floating share count of 55.48M. Insiders hold about 1.17% of the company’s shares, while institutions hold 65.08% stake in the company. Shares short for ZVRA as of 1755216000 were 6357218 with a Short Ratio of 5.11, compared to 1752537600 on 4895563. Therefore, it implies a Short% of Shares Outstanding of 6357218 and a Short% of Float of 11.3900006.
Earnings Estimates
The performance of Zevra Therapeutics Inc (ZVRA) in the stock market is under the watchful eye of 4.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.0, with high estimates of $0.04 and low estimates of -$0.03.
Analysts are recommending an EPS of between $1.62 and $0.99 for the fiscal current year, implying an average EPS of $1.22. EPS for the following year is $0.57, with 4.0 analysts recommending between $0.98 and $0.22.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $28.1M to a low estimate of $24.4M. As of the current estimate, Zevra Therapeutics Inc’s year-ago sales were $3.69MFor the next quarter, 8 analysts are estimating revenue of $28.12M. There is a high estimate of $30.2M for the next quarter, whereas the lowest estimate is $25.3M.
A total of 8 analysts have provided revenue estimates for ZVRA’s current fiscal year. The highest revenue estimate was $104.6M, while the lowest revenue estimate was $96M, resulting in an average revenue estimate of $101.03M. In the same quarter a year ago, actual revenue was $23.61MBased on 8 analysts’ estimates, the company’s revenue will be $155.85M in the next fiscal year. The high estimate is $183.1M and the low estimate is $135.6M.